264 related articles for article (PubMed ID: 30767446)
21. Clinical Development and Commercialization of Advanced Therapy Medicinal Products in the European Union: How Are the Product Pipeline and Regulatory Framework Evolving?
Boráň T; Menezes-Ferreira M; Reischl I; Celis P; Ferry N; Gänsbacher B; Krafft H; Lipucci di Paola M; Sladowski D; Salmikangas P
Hum Gene Ther Clin Dev; 2017 Sep; 28(3):126-135. PubMed ID: 28510497
[TBL] [Abstract][Full Text] [Related]
22. Regulation of cell-based therapeutic products intended for human applications in the EU.
Närhi MO; Nordström K
Regen Med; 2014 May; 9(3):327-51. PubMed ID: 24935044
[TBL] [Abstract][Full Text] [Related]
23. [Recording and reporting adverse reactions in clinical trials. New legal provisions according to the 12th Law Amending the German Drug Law (AMG) and the Ordinance on GCP (GCP-V)].
Eckhardt K; Cremer-Schaeffer P; König J; Paeschke N
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Feb; 48(2):173-80. PubMed ID: 15726458
[TBL] [Abstract][Full Text] [Related]
24. The Early Preclinical Development Program for Locally Administered Investigational Medicinal Products in Ophthalmology: Preclinical Data Required for Starting a First-in-Human Clinical Trial in Europe-Basic Considerations and 2 Case Studies.
Toggenburger A; Trönnberg R; Galland A; Mathis GA
Ther Innov Regul Sci; 2018 May; 52(3):321-328. PubMed ID: 29714531
[TBL] [Abstract][Full Text] [Related]
25. White paper on how to go forward with cell-based advanced therapies in Europe.
Erben RG; Silva-Lima B; Reischl I; Steinhoff G; Tiedemann G; Dalemans W; Vos A; Janssen RT; Le Blanc K; van Osch GJ; Luyten FP
Tissue Eng Part A; 2014 Oct; 20(19-20):2549-54. PubMed ID: 24749762
[TBL] [Abstract][Full Text] [Related]
26. [Regulatory requirements regarding cell-based medicinal products for human and veterinary use - a comparison].
Kuhlmann-Gottke J; Duchow K
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Nov; 58(11-12):1299-305. PubMed ID: 26369765
[TBL] [Abstract][Full Text] [Related]
27. The Food and Drug Administration and pragmatic clinical trials of marketed medical products.
Anderson ML; Griffin J; Goldkind SF; Zeitler EP; Wing L; Al-Khatib SM; Sherman RE
Clin Trials; 2015 Oct; 12(5):511-9. PubMed ID: 26374684
[TBL] [Abstract][Full Text] [Related]
28. [Approval of clinical trials with biological medicinal products].
Gross S; Jost N; Hartmann JP
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2017 Aug; 60(8):826-829. PubMed ID: 28677049
[TBL] [Abstract][Full Text] [Related]
29. From the Integrity of Potency Assays to Safe Clinical Intervention: Legal Perspectives.
Roslin W; Mansnérus J
Adv Exp Med Biol; 2023; 1420():151-163. PubMed ID: 37258789
[TBL] [Abstract][Full Text] [Related]
30. Fighting trafficking of falsified and substandard medicinal products in Russia.
Fayzrakhmanov NF
Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
[TBL] [Abstract][Full Text] [Related]
31. [The use of nanotechnology in medicinal products in the light of European Union law].
Jurewicz M
Pol Merkur Lekarski; 2014 Dec; 37(222):369-72. PubMed ID: 25715580
[TBL] [Abstract][Full Text] [Related]
32. GMP facilities for manufacturing of advanced therapy medicinal products for clinical trials: an overview for clinical researchers.
Alici E; Blomberg P
Curr Gene Ther; 2010 Dec; 10(6):508-15. PubMed ID: 21054243
[TBL] [Abstract][Full Text] [Related]
33. The legal landscape for advanced therapies: material and institutional implementation of European Union rules in France and the United Kingdom.
Mahalatchimy A; Rial-Sebbag E; Tournay V; Faulkner A
J Law Soc; 2012; 39(1):131-49. PubMed ID: 22530249
[TBL] [Abstract][Full Text] [Related]
34. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
Rossen BR
Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
[TBL] [Abstract][Full Text] [Related]
35. [European Marketing Authorisation: a long process. Experiences of small biotech companies with the ATMP regulation].
Buljovčić Z
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):831-8. PubMed ID: 21698536
[TBL] [Abstract][Full Text] [Related]
36. Compassionate use of unauthorized drugs: Legal regulations and ethical challenges.
Borysowski J; Górski A
Eur J Intern Med; 2019 Jul; 65():12-16. PubMed ID: 31036436
[TBL] [Abstract][Full Text] [Related]
37. The Current State of Advanced Therapy Medicinal Products in the Czech Republic.
Kočí Z; Boráň T; Krůpa P; Kubinová Š
Hum Gene Ther Clin Dev; 2018 Sep; 29(3):132-147. PubMed ID: 29869533
[TBL] [Abstract][Full Text] [Related]
38. Prospects of Advanced Therapy Medicinal Products-Based Therapies in Regenerative Dentistry: Current Status, Comparison with Global Trends in Medicine, and Future Perspectives.
Bakopoulou A
J Endod; 2020 Sep; 46(9S):S175-S188. PubMed ID: 32950189
[TBL] [Abstract][Full Text] [Related]
39. Legal instruments supporting the development of orphan medicinal products in the European Union.
Miaskowska-Daszkiewicz K
Acta Pol Pharm; 2014; 71(1):181-7. PubMed ID: 24779206
[TBL] [Abstract][Full Text] [Related]
40. [Regulation (EC) No. 1394/2007 on advanced therapy medicinal products : Incorporation into national law].
Dwenger A; Strassburger J; Schwerdtfeger W
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):14-9. PubMed ID: 20033662
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
